Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Plan B unprotected?

This article was originally published in The Tan Sheet

Executive Summary

Emergency contraceptive Plan B (levonorgestrel) helped drive Barr Pharmaceuticals' proprietary product sales up 12 percent to $438 million in 2007, executives said during the Montvale, N.J.-based firm's earnings call Feb. 28. While Barr would not break out sales for the "morning after pill," market information provider Information Resources, Inc. reports the drug drew $75.3 million in OTC sales in 2007, excluding sales at Wal-Mart, Club stores and C-Stores. CEO Bruce Downey says that while Barr has no patent on Plan B and exclusivity protection runs out in August 2009, the firm has a life cycle management strategy in place. Prescription products Adderall IR and Seasonique extended-cycle oral contraceptive also helped boost sales, the company says in a release. Barr expects Plan B, the contraceptive ParaGard and Seasonique to take its proprietary business "to new heights in 2008," projecting a 20 percent increase in sales. The firm posted overall 2007 revenue of $2.5 billion and net earnings of $128.4 million...

You may also be interested in...

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Pharmacogenetic Tests: US FDA Tries Off-Label Approach To Guide Consumers

US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts